ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,3461
0,00%
Bitcoin
69.339,56
0,01%
Brent Oil
79,395
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Oncocyte Corporation (OCX)

  7. Oncocyte Corporation (OCX) Notícias

OCX

Oncocyte (OCX)

Oncocyte Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCX
DataHoraFonteTítuloCódigoCompanhia
04/06/202418:02Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCXOncocyte Corporation
03/06/202415:13GlobeNewswire Inc.Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft StudyNASDAQ:OCXOncocyte Corporation
31/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
30/05/202417:47GlobeNewswire Inc.Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of MedicineNASDAQ:OCXOncocyte Corporation
23/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCXOncocyte Corporation
22/05/202418:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
17/05/202418:11Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:OCXOncocyte Corporation
15/05/202417:05GlobeNewswire Inc.Oncocyte Reports First Quarter 2024 Financial ResultsNASDAQ:OCXOncocyte Corporation
13/05/202409:00GlobeNewswire Inc.Oncocyte to Announce First Quarter 2024 Financial ResultsNASDAQ:OCXOncocyte Corporation
10/05/202418:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCXOncocyte Corporation
07/05/202410:19GlobeNewswire Inc.PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics MarketplaceNASDAQ:OCXOncocyte Corporation
12/04/202407:00GlobeNewswire Inc.Oncocyte Reports Full Year 2023 Financial ResultsNASDAQ:OCXOncocyte Corporation
11/04/202422:46GlobeNewswire Inc.Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesNASDAQ:OCXOncocyte Corporation
11/04/202418:30GlobeNewswire Inc.Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayNASDAQ:OCXOncocyte Corporation
09/04/202417:05GlobeNewswire Inc.Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:OCXOncocyte Corporation
16/01/202410:00GlobeNewswire Inc.Oncocyte to Present at the Sequire Investor Summit in Puerto RicoNASDAQ:OCXOncocyte Corporation
06/12/202310:00GlobeNewswire Inc.Oncocyte Begins FDA Submissions Process for VitaGraft Transplant AssaysNASDAQ:OCXOncocyte Corporation
09/11/202319:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCXOncocyte Corporation
09/11/202309:00GlobeNewswire Inc.Oncocyte Reports Third Quarter 2023 Financial ResultsNASDAQ:OCXOncocyte Corporation
03/11/202309:30GlobeNewswire Inc.Oncocyte to Announce Third Quarter 2023 Financial ResultsNASDAQ:OCXOncocyte Corporation
10/10/202317:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:OCXOncocyte Corporation
25/07/202310:08GlobeNewswire Inc.VitaGraft Kidney Expands Utility in Recurrent Primary Disease PatientsNASDAQ:OCXOncocyte Corporation
24/07/202314:35GlobeNewswire Inc.Oncocyte Announces 1-For-20 Reverse Stock SplitNASDAQ:OCXOncocyte Corporation
21/07/202318:16Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCXOncocyte Corporation
10/07/202312:20Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCXOncocyte Corporation
30/06/202317:14Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OCXOncocyte Corporation
27/06/202309:30GlobeNewswire Inc.Oncocyte Begins Manufacturing Transplant Blood TestNASDAQ:OCXOncocyte Corporation
13/06/202317:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OCXOncocyte Corporation
09/06/202307:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OCXOncocyte Corporation
19/05/202317:52Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:OCXOncocyte Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCX

Seu Histórico Recente

EU
N393S
N393S
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados